260981-45-1

Basic information

• Product Name: 4-(1-cyano-1-methyl-ethyl)-benzonitrile
• Synonyms: 4-(1-cyano-1-methyl-ethyl)-benzonitrile
• CAS NO: 260981-45-1
• Molecular Weight: 170.214
• Mol File: 260981-45-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-(1-cyano-1-methyl-ethyl)-benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-cyano-1-methyl-ethyl)-benzonitrile(260981-45-1)
• EPA Substance Registry System: 4-(1-cyano-1-methyl-ethyl)-benzonitrile(260981-45-1)

Safety Data

• Hazardous Substances Data: 260981-45-1(Hazardous Substances Data)

Upstream product

• 78-82-0 Isobutyronitrile 
• 1194-02-1 4-fluorobenzonitrile 
• 623-00-7 4-bromobenzenecarbonitrile 
• 623-03-0 4-Cyanochlorobenzene 
• 40119-34-4 2-methyl-2-(4-methylphenyl)propionitrile 
• 557-21-1 dicyanozinc 
• 876-31-3 4-(cyanomethyl)benzonitrile 
• 74-88-4 methyl iodide 
• 7321-55-3 2,2-dimethylmalononitrile 
• 460-00-4 1-Bromo-4-fluorobenzene 

Downstream Products

• 1006390-32-4 2-[4-(aminomethyl)phenyl]-2-methylpropanenitrile 
• 1146695-65-9 2-(4-formylphenyl)-2-methylpropanenitrile 

Relevant articles and documents

1,4-Dicarbofunctionalization of 4-Fluoroaryl Grignard and Lithium Reagents with Disubstituted Malononitriles

An efficient one-pot 1,4-dicarbofunctionalization of 4-fluoroaryl Grignard or lithium reagents with 2,2-disubstituted malononitriles is described. The reaction proceeds by sequential transnitrilation and SNAr reactions. Commercial Grignard solutions, Grignard reagents prepared in situ by halogen/magnesium exchange with i-PrMgCl, or aryllithium reagents prepared in situ by bromine/lithium exchange with n-BuLi are compatible with the reaction conditions. Moreover, 2,2-disubstituted malononitriles of diverse structures are accommodated. The reaction provides a unique approach to 1,4-dicarbofunctionalization of activated arenes in a tandem, one-pot transformation.

TRPV1 ANTAGONISTS

Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using

FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

A compound having a partial structure represented by Formula: or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease, diabetes and the like.